Literature DB >> 3967781

The effects of two doses of spironolactone on serum androgens and anagen hair in hirsute women.

R A Lobo, D Shoupe, P Serafini, D Brinton, R Horton.   

Abstract

Spironolactone (S) has been used successfully for the treatment of hirsutism. We evaluated whether the effects of S on serum androgens and hair growth are dose-related and whether S affects secreted androgens to the same degree as peripherally derived androgens. Two groups of 15 hirsute patients, similarly matched, received either 100 or 200 mg S daily for 3 months. Serum total testosterone (T) decreased significantly (P less than 0.05) and to a similar degree with both dosages, whereas unbound T was unaltered. Dehydroepiandrosterone sulfate was unaltered, whereas androstenedione decreased with 200 mg S (P less than 0.05). Peripherally derived serum dihydrotestosterone decreased to a similar degree with 100 and 200 mg S (P less than 0.05), whereas 5 alpha-androstane-3 alpha-17 beta-diol (3 alpha-diol) increased (P less than 0.05) similarly with both dosages. Serum 3 alpha-diol glucuronide (3 alpha-diol-G) increased with both dosages, but not significantly. Anagen hair shaft diameters decreased significantly in both groups by 19% +/- 8% and 30% +/- 4% (P less than 0.05). No correlation was found between hair growth and serum androgens. Because serum unbound T was largely unaltered by S, it is suggested that the antiandrogenic effects of S are primarily related to its peripheral effect. However, there is no good clinical marker for this effect as levels of 3 alpha-diol and 3 alpha-diol-G increase.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3967781     DOI: 10.1016/s0015-0282(16)48373-1

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  18 in total

Review 1.  Hirsutism: pilosebaceous unit dysregulation. Role of peripheral and glandular factors.

Authors:  V Toscano
Journal:  J Endocrinol Invest       Date:  1991-02       Impact factor: 4.256

2.  Developmental patterns of serum 3 alpha-androstanediol glucuronide.

Authors:  H L Rittner; P D Lee; W F Blum; H G Doerr; J Steiss; J Kreuder; W Rascher; W Kiess
Journal:  J Endocrinol Invest       Date:  1997-05       Impact factor: 4.256

Review 3.  The role of androgen and androgen receptor in skin-related disorders.

Authors:  Jiann-Jyh Lai; Philip Chang; Kuo-Pao Lai; Lumin Chen; Chawnshang Chang
Journal:  Arch Dermatol Res       Date:  2012-07-25       Impact factor: 3.017

4.  Developmental patterns of serum 3 alpha-androstanediol glucuronide.

Authors:  H L Rittner; P D Lee; W F Blum; H G Doerr; J Steiss; J Kreuder; W Rascher; W Kiess
Journal:  J Endocrinol Invest       Date:  1997-03       Impact factor: 4.256

Review 5.  Hirsutism and the effectiveness of spironolactone in its management.

Authors:  G R McMullen; A J Van Herle
Journal:  J Endocrinol Invest       Date:  1993-12       Impact factor: 4.256

Review 6.  Safety of 5α-reductase inhibitors and spironolactone in breast cancer patients receiving endocrine therapies.

Authors:  Raquel N Rozner; Azael Freites-Martinez; Jerry Shapiro; Eliza B Geer; Shari Goldfarb; Mario E Lacouture
Journal:  Breast Cancer Res Treat       Date:  2018-11-22       Impact factor: 4.872

7.  Spironolactone in the treatment of idiopathic hirsutism and the polycystic ovary syndrome.

Authors:  D J Evans; C W Burke
Journal:  J R Soc Med       Date:  1986-08       Impact factor: 5.344

8.  The effects of spironolactone on testosterone fractions and sex-hormone binding globulin binding capacity in hirsute women.

Authors:  J A Marcondes; S L Minanni; W W Luthold; A C Lerário; M Nery; B B Mendonça; B L Wajchenberg; M A Kirschner
Journal:  J Endocrinol Invest       Date:  1995-06       Impact factor: 4.256

Review 9.  Alopecia and hirsuties. Current concepts in pathogenesis and management.

Authors:  J H Barth
Journal:  Drugs       Date:  1988-01       Impact factor: 9.546

10.  Lack of endocrine systemic side effects after topical application of spironolactone in man.

Authors:  F O Rey; C Valterio; L Locatelli; A A Ramelet; J P Felber
Journal:  J Endocrinol Invest       Date:  1988-04       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.